Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
Allogene Therapeutics stock last closed at $1.37, down 2.19% from the previous day, and has decreased 47.45% in one year. It has overperformed other stocks in the Biotechnology industry by 0.04 percentage points. Allogene Therapeutics stock is currently +58.93% from its 52-week low of $0.86, and -63.76% from its 52-week high of $3.78.
There are currently 224.73M shares of ALLO outstanding. The market cap of ALLO is $307.88M. In the last 24 hours, 1.95M ALLO shares were traded.
How to Buy Allogene Therapeutics Stock
Wondering how to invest in Allogene Therapeutics stock? Here's how.
Decide where to buy Allogene Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you determine where to buy Allogene Therapeutics stock.
Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Fund your brokerage account: Choose your payment method and add your details.
Analyze Allogene Therapeutics stock: The Allogene Therapeutics ticker symbol is ALLO. Is Allogene Therapeutics stock a good investment? Should you buy shares of ALLO? How do ALLO's underlying business fundamentals look? Do top analysts think Allogene Therapeutics is a good buy? Why has ALLO's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if ALLO is a good stock to buy).
Execute your ALLO trade: Decide if you will purchase ALLO shares at the current market price or use a limit order to purchase ALLO stock at a specific price.
Track your investment in ALLO: Create a watchlist to watch your new investment in Allogene Therapeutics stock.
Step 1: Decide where to buy Allogene Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy ALLO shares.
A brokerage account enables you to buy and sell a variety of investments, including stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
In our opinion, eToro is the best brokerage. Here's why:
Invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to world financial markets: From Tech to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for a brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal details so you are able to buy ALLO stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Allogene Therapeutics stock
Once you have chosen the best place to buy Allogene Therapeutics stock, it's very important to research their stock prior to buying, so you can wrap your head around the risk and upside.
Allogene Therapeutics Metrics
ALLO Price
$1.37
1w %
-1.47%
1y %
-47.45%
5y %
-95.75%
P/E
-1.4x
P/B
0.98x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$212.02M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$307.88M
Next Earnings
N/A
Next Dividend
N/A
ALLO Fundamentals
WallStreetZen was built to help part-time investors perform better fundamental analysis in minutes instead of hours.
Last year, ALLO revenue was $0.00. In the past 4 year, ALLO's revenue has gone up by -100% per year. This was slower than the Biotechnology industry average of 44.13%.
What are ALLO executives and large shareholders up to?
Over the past 12 months, insiders at ALLO have sold more shares than they have bought.
Benjamin Machinas Beneski, SVP Chief Technical Officer of ALLO, was the latest ALLO insider to sell. They sold $958.92 worth of ALLO stock on Nov 17, 2025.
No, Allogene Therapeutics doesn't provide an income stream by paying out dividends.
ALLO Social Trading Data
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your ALLO trade
There are two main types of orders:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are generally the best for newer investors.
Limit order: A limit order lets you buy or sell a security at a specific price (or better). If you want to be certain you're buying or selling at a specific price, place a limit order.
Press the Open Trade button and your broker will place the order.
If you need additional help with investing in stocks on eToro, click the how to video below:
How much does it cost to buy one Allogene Therapeutics share?
As of Dec 1, 2025, it costs $1.37 to buy one share of Allogene Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $0.69, you can buy 0.5 shares of ALLO.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.